CBD 600mg Normalizes Neuroendocrine and Anxiety Responses to Stress in Patients at Risk of Psychosis
Psychopharmacology. 2020;237:1121-1130Thirty-two participants at clinical high risk (CHR) for psychosis were randomized to receive either cannabidiol (CBD) 600 mg/day (CHR-CBD) or placebo (CHR-P) for one week. The CHR participants and 25 healthy controls (HC) then performed a psychosocial stress task. The primary outcome was the neuroendocrine response to stress measured by serum cortisol levels. Other outcomes of interest included subjective measures of anxiety and stress associated with public speaking. Between the HC, CHR-CBD, and CHR-P groups, in order, a significant linear decrease in cortisol levels was observed alongside significant linear increases in both anxiety and stress, suggesting beneficial effects of CBD treatment.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
